Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.

Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA.

J Clin Rheumatol. 2014 Dec;20(8):427-32. doi: 10.1097/RHU.0000000000000200. Review.

2.

Tofacitinib versus methotrexate in rheumatoid arthritis.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators..

N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476.

3.

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA.

Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318.

4.

Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.

Dalbeth N, Doyle AJ, McQueen FM, Sundy J, Baraf HS.

Arthritis Care Res (Hoboken). 2014 Jan;66(1):82-5. doi: 10.1002/acr.22059.

5.

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP.

Arthritis Res Ther. 2013 Feb 1;15(1):R25. doi: 10.1186/ar4159.

6.

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA; ORAL Scan Investigators..

Arthritis Rheum. 2013 Mar;65(3):559-70. doi: 10.1002/art.37816.

7.
8.

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS.

Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795.

9.

Effectiveness and Safety of a Multicenter Extension and Retreatment Trial of Gel-200 in Patients with Knee Osteoarthritis.

Strand V, Baraf HS, Lavin PT, Lim S, Hosokawa H.

Cartilage. 2012 Oct;3(4):297-304. doi: 10.1177/1947603512451024.

11.

2011 recommendations for the diagnosis and management of gout and hyperuricemia.

Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, Lieberman JA 3rd, Mandel DR, Mandelbrot DA, McClain BP, Mizuno E, Morton AH, Mount DB, Pope RS, Rosenthal KG, Setoodeh K, Skosey JL, Edwards NL.

Phys Sportsmed. 2011 Nov;39(4):98-123. doi: 10.3810/psm.2011.11.1946. Review.

PMID:
22293773
12.

Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities.

Baraf HS, Gold MS, Petruschke RA, Wieman MS.

Am J Geriatr Pharmacother. 2012 Feb;10(1):47-60. doi: 10.1016/j.amjopharm.2011.12.002.

PMID:
22264852
13.

2011 Recommendations for the diagnosis and management of gout and hyperuricemia.

Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, Lieberman JA 3rd, Mandel DR, Mandelbrot DA, McClain BP, Mizuno E, Morton AH, Mount DB, Pope RS, Rosenthal KG, Setoodeh K, Skosey JL, Edwards NL; European League Against Rheumatism..

Postgrad Med. 2011 Nov;123(6 Suppl 1):3-36. doi: 10.3810/pgm.2011.11.2511.

PMID:
22156509
14.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
15.
16.

Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial.

Baraf HS, Gold MS, Clark MB, Altman RD.

Phys Sportsmed. 2010 Jun;38(2):19-28. doi: 10.3810/psm.2010.06.1779.

PMID:
20631460
17.

Resolution of gouty tophi after twelve weeks of pegloticase treatment.

Baraf HS, Matsumoto AK, Maroli AN, Waltrip RW 2nd.

Arthritis Rheum. 2008 Nov;58(11):3632-4. doi: 10.1002/art.23993. No abstract available.

18.

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study Investigators..

Arthritis Rheum. 2008 Sep;58(9):2882-91. doi: 10.1002/art.23810.

19.

A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout.

Taylor WJ, Schumacher HR Jr, Baraf HS, Chapman P, Stamp L, Doherty M, McQueen F, Dalbeth N, Schlesinger N, Furst DE, Vazquez-Mellado J, Becker MA, Kavanaugh A, Louthrenoo W, Bardin T, Khanna D, Simon LS, Yamanaka H, Choi HK, Zeng X, Strand V, Grainger R, Clegg D, Singh JA, Diaz-Torne C, Boers M, Gow P, Barskova VG.

Ann Rheum Dis. 2008 Jun;67(6):888-91. Erratum in: Ann Rheum Dis. 2008 Nov;67(11):1652.. Mellado, J Vazquez [corrected to Vazquez-Mellado, J].

PMID:
18055475
20.

Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.

Baraf HS.

Curr Pharm Des. 2007;13(22):2228-36. Review.

PMID:
17691996
Items per page

Supplemental Content

Loading ...
Support Center